Prostate-specific antigen density: The role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma

1995 ◽  
Vol 27 (6) ◽  
pp. 757-761
Author(s):  
L. I§ikay ◽  
Ö. Yaman ◽  
M. Bozlu ◽  
Y. Z. Müftüoĝlu ◽  
O. Göĝü§
Keyword(s):  
Prostate Specific Antigen ◽  
Prostate Carcinoma ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Prostate Hyperplasia ◽  
Prostate Specific Antigen Density ◽  
Benign Prostate

scholarly journals Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Jen Hsiao ◽  
Tzong-Shin Tzai ◽  
Chein-Hung Chen ◽  
Wen-Horng Yang ◽  
Chung-Hsuan Chen
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Clinical Sample ◽  
Specific Antigen ◽  
Ion Accumulation ◽  
Detection Sensitivity ◽  
Prostate Hyperplasia ◽  
Liquid Chromatography Tandem Mass ◽  
Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

scholarly journals Hubungan antara Kadar Prostate Specific Antigen Serum dan Skor Gleason pada Adenokarsinoma Prostat

2019 ◽  
Vol 30 (3) ◽  
pp. 181
Author(s):  
Claudia Clary Navisa ◽  
Willy Sandhika ◽  
Heny Arwati
Keyword(s):  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Prostate Hyperplasia ◽  
Benign Prostate

<p>Kanker prostat adalah kanker terbanyak ke empat di dunia dan merupakan kanker terbanyak ke dua yang menyerang pria. Pada tahun 2013, angka kejadian kanker prostat di Indonesia adalah 25.012 dengan jumlah kasus terbesar yaitu di Jawa Timur sebanyak 5.668. Prostate Specific Antigen (PSA) sebagai penanda tumor, dikatakan berhubungan secara linier dengan skor Gleason. Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara kadar PSA serum dengan skor Gleason pada pasien kanker prostat di RSUD Dr. Soetomo. Penelitian ini merupakan studi analitik dengan desain belah lintang. Data penelitian dikumpulkan dari data rekam medis pasien kanker prostat yang menjalani pemeriksaan kadar PSA serum dan histopatologi jaringan prostat di RSUD Dr. Soetomo Surabaya pada tahun 2015-2017. Pasien dengan Benign Prostate Hyperplasia, infeksi saluran kencing, dan prostatitis dalam 1 bulan terakhir dimasukkan ke dalam kriteria eksklusi. Pada penelitian ini didapatkan 62 sampel. Rentang usia sampel 28-85 tahun dengan proporsi terbanyak pada kelompok usia 58-72 tahun, yaitu sebesar 66,7%. Dari keseluruhan sampel, 41,3% memiliki nilai kadar PSA serum &gt;99ng/dL dan 85,5% memiliki skor Gleason yang buruk. Hasil uji Spearman menunjukkan adanya hubungan yang bermakna (r=0,216; p=0,046) antara kadar PSA serum dan skor Gleason pada pasien kanker prostat di RSUD Dr. Soetomo Surabaya. </p>

Sign in / Sign up

Export Citation Format

Share Document